LMO2蛋白表达在T淋巴母细胞淋巴瘤/急性淋巴细胞白血病与胸腺瘤鉴别诊断中的应用
| 作者: |
1张婷婷,
1朱培培,
1毕珂,
2芮炜玮,
3李冰,
1黄丹丹,
1刘玉婷,
1张灏杨,
1易祥华,
1曾郁
1 同济大学附属同济医院病理科，上海 200065 2 上海交通大学医学院附属瑞金医院病理科，上海 200010 3 同济大学附属同济医院血液科，上海 200065 |
| 通讯: |
易祥华
Email: yixhxf@163.com 曾郁 Email: yuzeng2013@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2022.05.005 |
| 基金: | 国家自然科学基金(81401882)；同济大学“中央高校基本科研业务费专项资金”(22120170004)；上海市同济医院临床研究培育项目[ITJ(QN)1907]；上海市卫生和计划生育委员会青年项目(20174Y0110)。 |
摘要
目的：探讨LMO2蛋白免疫组织化学染色在T淋巴母细胞淋巴瘤/急性淋巴细胞白血病(T lymphoblastic lymphoma/acute lymphocytic leukaemia，T-LBL/ALL)与胸腺瘤鉴别诊断中的价值。方法：对34例T-LBL/ALL及38例胸腺瘤组织应用免疫组织化学EnVision两步法进行LMO2标记。结果：29例T-LBL/ALL肿瘤细胞LMO2染色阳性(29/34，阳性率85.3%)，38例胸腺瘤(A型3例、AB型14例、B1型10例、B2型5例、B3型4例、C型2例)肿瘤性T淋巴细胞LMO2均阴性。LMO2蛋白表达在T-LBL/ALL和胸腺瘤之间差异有统计学意义(P<0.001)。结论：LMO2可作为T-LBL/ALL与胸腺瘤鉴别诊断的标志物。
关键词：
淋巴瘤；淋巴母细胞淋巴瘤；急性淋巴细胞白血病；胸腺瘤；LMO2；诊断；鉴别
Application of LMO2 protein expression in the differential diagnosis of T lymphoblastic lymphoma/acute lymphocytic leukemia and thymoma
CorrespondingAuthor: YI Xianghua Email: yixhxf@163.com
DOI: 10.3978/j.issn.2095-6959.2022.05.005
Foundation: This work was supported by the National Natural Science Foundation (81401882), The Fundamental Research Funds for the Central Universities, Tongji University (22120170004), Clinical Research Project of Tongji Hospital of Tongji University [ITJ(QN)1907], and Youth Project of Scientific Research Project of Shanghai Health and Family Planning Commission (20174Y0110), China.
Abstract
Objective: To explore the value of immunohistochemical staining of LMO2 protein in the differential diagnosis of T-lymphoblastic lymphoma/acute lymphocytic leukemia (T-LBL/ALL) and thymoma. Methods: Thirty-four cases of T-LBL/ALL and 38 cases of thymoma were labeled with LMO2 using immunohistochemical EnVision two-step method. Results: Neoplastic cells of 29 cases of T-LBL/ALL were positive for LMO2 staining (29/34, positive rate 85.3%), however, neoplastic T lymphocytes of 38 cases of thymoma including 3 cases of type A, 14 cases of type AB, 10 cases of type B1, 5 cases of type B2, 4 cases of type B3, 2 cases of type C were negative for LMO2 staining. The expression of LMO2 protein was significantly different between T-LBL/ALL and thymoma (P<0.001). Conclusion: LMO2 can be used as a marker for the differential diagnosis of T-LBL/ALL and thymoma.
Keywords：
lymphoma; lymphoblastic lymphoma; acute lymphocytic leukemia; thymoma; LMO2; diagnosis; differentiation